- Clinical Trials
- April 2025
- 40 Pages
Global
From €1121EUR$1,250USD£958GBP
- Report
- May 2024
- 200 Pages
Global
From €3723EUR$4,150USD£3,180GBP
- Report
- May 2026
- 200 Pages
South Korea
From €2502EUR$2,789USD£2,137GBP
- Report
- June 2024
- 140 Pages
Asia Pacific
From €3471EUR$3,869USD£2,965GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3471EUR$3,869USD£2,965GBP
- Report
- June 2024
- 140 Pages
Europe
From €3471EUR$3,869USD£2,965GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3364EUR$3,750USD£2,874GBP
- Report
- September 2022
- 30 Pages
Global
From €2467EUR$2,750USD£2,108GBP
- Report
- July 2024
- 70 Pages
Global
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 90 Pages
South Korea
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 70 Pages
India
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 90 Pages
United States
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 90 Pages
France
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 70 Pages
Russia
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 160 Pages
Middle East, Africa
From €4262EUR$4,750USD£3,640GBP
- Report
- February 2024
- 90 Pages
Europe
From €4262EUR$4,750USD£3,640GBP

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes.
Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain.
Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more